Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
ANAHEIM, CA, April 09, 2018 -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, and legendary soul man Sam Moore appeared as guests on Fox Business Network’s Mornings with Maria this morning to discuss the company's naltrexone implant and how it helps combat opioid addiction.
"Mornings with Maria" features anchor Maria Bartiromo alongside a roundtable of rotating industry titans and economic experts discussing the major news and themes driving the business day and the market moves. You can view the segment here: https://www.foxbusiness.com/features/legendary-soul-man-sam-moore-backs-new-implant-to-treat-opioid-addiction.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. [email protected] 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 [email protected]
